Yoram B.
- Country
- France
- Department
- Institut des MICI
Research Overview
- Phase 3b, Randomized, Open‑Label, Active‑Controlled Trial Comparing Guselkumab Versus Risankizumab for Efficacy and Safety in Moderately to Severely Active Crohn’s Disease
- Phase 3 Randomized Double‑Blind Study Evaluating Efficacy and Safety of JNJ‑78934804 Combination Therapy versus Guselkumab in Moderately to Severely Active Crohn’s Disease
- Phase 3 Randomized Double‑Blind Trial of JNJ‑78934804 Combination Therapy vs Guselkumab in Moderately to Severely Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 253 of 401 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating complex manifestations of inflammatory bowel diseases, with particular emphasis on both ulcerative colitis and Crohn's disease.
- Moderate to severe disease variants
- Long-term therapeutic approaches
- Novel treatment modalities
Their work encompasses comprehensive management strategies for patients with varying disease severities.
Advanced Therapeutic Applications
The investigator focuses on innovative therapeutic approaches including biological therapies and targeted treatments for inflammatory bowel conditions.
- Combination therapy protocols
- Treatment optimization strategies
- Patient monitoring systems
Their expertise extends to evaluating novel therapeutic agents and treatment combinations.
Specialized Disease Management
Special attention is given to complex disease manifestations, particularly fistulizing perianal Crohn's disease and post-operative recurrence management.
- Perianal fistula treatment
- Post-surgical care protocols
- Recurrence prevention strategies
The investigator employs advanced therapeutic approaches for complicated disease presentations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.